LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma

References

• Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Huang J, Koulaouzidis A, Marlicz W et al. Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries. Cancers (Basel) 13(1), 141 (2021).
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021).
   PubMed Web of Science ®Google Scholar
• Then EO, Lopez M, Saleem S et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J. Oncol. 11(2), 55–64 (2020).
   PubMedGoogle Scholar
• Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(10), 1005–1020 (2022).
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology. Esophageal and esophagogastric junction cancers version 2.2022. www.nccn.org/guidelines/guidelines-detail?category=1&id=1433 (04/21/2022).
   Google Scholar
• Sun JM, Shen L, Shah MA et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, Phase III study. Lancet 398(10302), 759–771 (2021).
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10), 916–925 (2021).
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386(5), 449–462 (2022).
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cui C, Yao J et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center Phase III trial. Cancer Cell 40(3), 277–288 (2022).
   PubMed Web of Science ®Google Scholar
• Shen L, Lu ZH, Wang JY et al. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the Phase III ORIENT-15 study. Ann. Oncol. 32, S1330 (2021).
   Web of Science ®Google Scholar
• Yoon H, Kato K, Raymond E et al. LBA-1 RATIONALE-306: randomized, global, placebo-controlled, double-blind Phase III study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ann. Oncol. 33, S375 (2022).
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Vrána D, Matzenauer M, Neoral Č et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int. J. Mol. Sci. 20(1), 13 (2018).
   PubMed Web of Science ®Google Scholar
• Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J. Gastrointest Oncol. 6(5), 561–569 (2015).
   PubMed Web of Science ®Google Scholar
• Cui C, Yu B, Jiang Q, Li X, Shi K, Yang Z. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. Clin. Exp. Pharmacol. Physiol. 46(1), 3–10 (2019).
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11(8), 2947–2953 (2005).
   PubMed Web of Science ®Google Scholar
• Svensson MC, Borg D, Zhang C et al. Expression of PD-L1 and PD-1 in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma: relationship with mismatch repair status and survival. Front. Oncol. 9, 136 (2019).
   PubMed Web of Science ®Google Scholar
• Wakita A, Motoyama S, Nanjo H et al. PD-L1 expression is a prognostic factor in patients with thoracic esophageal cancer treated without adjuvant chemotherapy. Anticancer Res. 37(3), 1433–1441 (2017).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Lo AWI, Wong A et al. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget 8(18), 30175–30189 (2017).
   PubMedGoogle Scholar
• Yagi T, Baba Y, Ishimoto T et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. Ann. Surg. 269(3), 471–478 (2019).
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K et al. Randomized Phase III keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138–4148 (2020).
   PubMed Web of Science ®Google Scholar
• KEYTRUDA^® (pembrolizumab) injection, for intravenous use. Merck & Co., Inc., Rahway, NJ, USA (2023).
   Google Scholar
• Doi T, Piha-Paul SA, Jalal SI et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J. Clin. Oncol. 36(1), 61–67 (2018).
   PubMed Web of Science ®Google Scholar
• Shah MA, Kojima T, Hochhauser D et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the Phase II KEYNOTE-180 Study. JAMA Oncol. 5(4), 546–550 (2019).
   PubMed Web of Science ®Google Scholar
• Zhu C, Ma X, Hu Y et al. Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget 7(28), 44545–44557 (2016).
   PubMedGoogle Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15(5), 325–340 (2018).
   PubMed Web of Science ®Google Scholar
• Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell 176(6), 1248–1264 (2019).
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat. Rev. Cancer 13(12), 871–882 (2013).
   PubMed Web of Science ®Google Scholar
• Gockel I, Moehler M, Frerichs K et al. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol. Rep. 20(4), 845–850 (2008).
   PubMed Web of Science ®Google Scholar
• Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR signaling in cancer. Clin. Cancer Res. 21(12), 2684–2694 (2015).
   PubMed Web of Science ®Google Scholar
• Wada J, Suzuki H, Fuchino R et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 29(3), 881–888 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Onishi H, Wada J et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur. J. Immunol. 40(1), 197–203 (2010).
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73(2), 539–549 (2013).
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Rigamonti N, Kadioglu E et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 9(385), eaak9670 (2017).
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T-cells in tumors. J. Exp. Med. 212(2), 139–148 (2015).
   PubMed Web of Science ®Google Scholar
• Capozzi M, De Divitiis C, Ottaiano A et al. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag. Res11. 3847–3860 (2019).
   Web of Science ®Google Scholar
• Nair A, Lemery SJ, Yang J et al. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin. Cancer Res. 21(23), 5205–5208 (2015).
   PubMed Web of Science ®Google Scholar
• Nair A, Reece K, Donoghue MB et al. FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma. Oncologist 26(3), e484–e491 (2021).
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T-cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLOS ONE 14(2), e0212513 (2019).
   PubMed Web of Science ®Google Scholar
• Kimura T, Kato Y, Ozawa Y et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 109(12), 3993–4002 (2018).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsui J, Matsushima T et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc. Cell 6, 18 (2014).
   PubMedGoogle Scholar
• Taylor MH, Lee CH, Makker V et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 38(11), 1154–1163 (2020).
   PubMed Web of Science ®Google Scholar
• Lee CH, Shah AY, Rasco D et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a Phase Ib/2 study. Lancet Oncol. 22(7), 946–958 (2021).
   PubMed Web of Science ®Google Scholar
• Makker V, Taylor MH, Aghajanian C et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J. Clin. Oncol. 38(26), 2981–2992 (2020).
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 38(26), 2960–2970 (2020).
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Fukuoka S, Nakamura Y et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, Phase II trial. Lancet Oncol. 21(8), 1057–1065 (2020).
   PubMed Web of Science ®Google Scholar
• FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma (01/12/2022).
   Google Scholar
• Makker V, Colombo N, Casado Herráez A et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 386(5), 437–448 (2022).
   PubMed Web of Science ®Google Scholar
• FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma (10/05/2022).
   Google Scholar
• Taylor MH, Schmidt EV, Dutcus C et al. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 17(6), 637–648 (2021).
   PubMed Web of Science ®Google Scholar
• Cohen DJ, Tabernero J, Van Cutsem E et al. A randomized Phase III study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. J. Clin. Oncol. 40(Suppl. 4), TPS369 (2022).
   Web of Science ®Google Scholar
• Arance A, De La Cruz-Merino L, Petrella TM et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J. Clin. Oncol. 41(1), 75–85 (2022).
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 Phase III Randomized Clinical Trial. JAMA Oncol. 6(10), 1571–1580 (2020).
   PubMed Web of Science ®Google Scholar
• Nishio M, Horai T, Horiike A et al. Phase I study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br. J. Cancer 109(3), 538–544 (2013).
   PubMed Web of Science ®Google Scholar
• Nishio M, Peled N, Zer A et al. 1313P Phase III LEAP-006 safety run-in (part 1): 1L pembrolizumab (pembro) + chemotherapy (chemo) with lenvatinib (len) for metastatic NSCLC. Ann. Oncol. 31, S848–S849 (2020).
   Web of Science ®Google Scholar
• Gupta A, Koetz B, Hanekom W, O'brien JP, Wanders J, Jansen M. Population pharmacokinetics (PK) and exposure/response relationships of the receptor tyrosine kinase inhibitor E7080 in phase I studies. Eur. J. Can. Suppl. 8(7), 143 (2010).
   Google Scholar
• Motzer R, Alekseev B, Rha SY et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384(14), 1289–1300 (2021).
   PubMed Web of Science ®Google Scholar